Can gabapentin cause new‑onset bradycardia and chest congestion in a patient?

Gabapentin and Bradycardia/Chest Congestion

Gabapentin can cause bradycardia and cardiovascular depression, but chest congestion is not a recognized adverse effect of this medication. The bradycardia is a documented cardiovascular side effect that occurs through central and peripheral mechanisms, while respiratory symptoms like "chest congestion" should prompt evaluation for alternative causes including heart failure, pulmonary edema, or concurrent illness.

Bradycardia: A Documented Cardiovascular Effect

Gabapentin definitively causes bradycardia through multiple mechanisms:

• Central mechanism: Gabapentin reduces blood pressure and heart rate through action on the nucleus tractus solitarii (NTS), the primary cardiovascular control center in the brainstem, via nitric oxide synthase signaling pathways 1

• Direct cardiac effects: Recent preclinical evidence demonstrates that both acute and chronic gabapentin treatment suppress cardiovascular function, causing hypotension, bradycardia, and left ventricular systolic dysfunction through abnormal calcium signaling in cardiomyocytes (specifically upregulation of calmodulin) 2

• Vascular effects: Gabapentinoids decrease myogenic tone in arteries, causing vasodilation independent of L-type calcium channel blockade 3

The FDA label does not list bradycardia or cardiac conduction abnormalities as warnings for gabapentin 4. However, this represents a gap in labeling rather than absence of effect, as multiple high-quality studies demonstrate cardiovascular depression.

Timing and Dose-Response

The cardiovascular effects follow predictable patterns:

• Acute effects: Immediate bradycardia and hypotension occur within minutes of IV administration 2
• Chronic effects: Sustained bradycardia develops with daily dosing over 7+ days 2
• Dose-dependent: Higher doses (800 mg) produce more pronounced heart rate and blood pressure reductions compared to 400 mg 5

"Chest Congestion": Not a Gabapentin Effect

The FDA label does not list chest congestion, pulmonary symptoms, or respiratory congestion as adverse effects of gabapentin 4. The documented respiratory effects are limited to:

• Pharyngitis (3% vs 2% placebo)
• Bronchitis and respiratory infection in pediatric patients
• Dyspnea (equally common in placebo)

Critical distinction: If a patient on gabapentin develops what appears to be "chest congestion," consider:

1. Gabapentin-induced heart failure: Peripheral edema occurs in 8% of patients 4, and recent evidence shows gabapentinoids increase risk of acute heart failure, particularly after dose escalation 3. Heart failure can present with pulmonary congestion that may be described as "chest congestion"

2. Peripheral edema misattribution: The 8% incidence of peripheral edema 4 occurs through vasodilatory mechanisms 3, with median onset of 23 days and rapid resolution (7 days) after discontinuation

3. Concurrent illness: Upper respiratory infections, pneumonia, or other pulmonary pathology unrelated to gabapentin

Clinical Management Algorithm

If bradycardia is present:

• Document heart rate and blood pressure trends
• Review gabapentin dose and duration (higher doses and chronic use increase risk)
• Consider dose reduction or discontinuation if symptomatic or HR <50 bpm
• Monitor for concurrent hypotension and signs of cardiac dysfunction 2

If "chest congestion" is present:

• Examine for signs of heart failure (peripheral edema, elevated JVP, pulmonary rales)
• Check for peripheral edema (8% incidence with gabapentin) 4
• If heart failure suspected: Consider echocardiography and discontinue gabapentin (resolution typically within 7 days) 3
• If no cardiac findings: Evaluate for respiratory infection or other pulmonary pathology

Important Caveats

Cardiovascular risk stratification: A 2025 systematic review found gabapentinoids increase risk of myocardial infarction after 1 year of use (HR 1.31) and stroke after 5 years (HR 1.44) 6. Patients with pre-existing cardiovascular disease warrant closer monitoring.

Drug interactions: The guideline on psychotropic medications notes that lithium causes bradycardia, T-wave changes, and AV block 7. If gabapentin is combined with other medications affecting heart rate (beta-blockers, calcium channel blockers, lithium), additive bradycardic effects may occur.

Withdrawal considerations: While baclofen (another GABA-ergic agent) withdrawal causes severe bradyarrhythmia 8, gabapentin withdrawal primarily causes seizure risk in epilepsy patients 4, not cardiac effects.

Monitoring: Unlike the FDA recommendations for methadone (baseline and follow-up ECGs) 7, no specific cardiac monitoring is mandated for gabapentin. However, given the emerging cardiovascular evidence, baseline heart rate and blood pressure documentation is prudent, with periodic reassessment in high-risk patients.